|
|
Message below is a paid advertisement. Content is provided by the sponsor.
|
| |
A SPECIAL
ANNOUNCEMENT FROM: |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Otic Chronicle
A Guide to Conducting Nonclinical Safety Studies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Developments
for new therapeutics to target various aspects of auditory system
dysfunction is on the rise within the drug development industry, as
developers seek to combat otic disorders that inhabit the processing of
appropriate auditory responses. Join Rachel as she reviews nonclinical auditory safety programs.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Register now to hear from your presenter for the upcoming webinar, The Otic Chronicle | A guide to Conducting Nonclinical Safety Studies, on Thursday, August 17 at 10 AM EDT. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rachel will address
- Otic therapeutics within the drug development industry
- Commonly asked questions regarding timelines & species |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rachel Tapp, MS, LATG, is a
Senior Study Director for neurobehavioral sciences at MPI Research. As an
expert with more than 15 years of experience, she ensures high level
performance of regulatory and non-regulatory contracted neurobehavioral
ototoxicity studies, focusing on study management, communication, and
fostering Sponsor relationships.She has authored many auditory safety
posters and articles and is an active member of the Association for
Research in Otolaryngology, the Society for Neuroscience, and the Safety
Pharmacology Society. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
You received this email because you are a customer of PHTE, a UBM publication. You are on the mailing list as %%emailaddress%%.
|
|
